4CPS-128 Effectiveness of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer

BACKGROUND: Abiraterone acetate (AA) and enzalutamide are authorised oral therapies in the treatment of metastatic castration-resistant prostate cancer (mCRPC), which act by inhibiting androgen synthesis. PURPOSE: To compare the effectiveness of AA and enzalutamide in patients with mCRPC. MATERIAL A...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Eur J Hosp Pharm
Prif Awduron: García, AM Sánchez, Mateos, A Andújar, Esquerdo, M Llinares, Irigaray, L Soriano, Torres, R Antón, Ruiz, A Navarro
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BMJ Group 2018
Pynciau:
Section 4: Clinical pharmacy services
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535815/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.219
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg